ライフサイエンスコーパス: antihypertensive agent

1 ne parenteral (bolus or continuous infusion) antihypertensive agent.

2 renin to be approved for clinical use as an antihypertensive agent.

3 doxazosin is a safe and effective third-line antihypertensive agent.

4 in a 6-month period and were taking a single antihypertensive agent.

5 ctive synthesis of indolodioxane U86192A, an antihypertensive agent.

6 promising natural source of antioxidants and antihypertensive agents.

7 ide-effect profiles prior to clinical use as antihypertensive agents.

8 latency of cancer, and heterogeneous use of antihypertensive agents.

9 pon reduction of MI when compared with other antihypertensive agents.

10 educe LV mass to a greater extent than other antihypertensive agents.

11 3 inhibitors might be therapeutically useful antihypertensive agents.

12 function to a greater extent than can other antihypertensive agents.

13 lism that are not shared by other classes of antihypertensive agents.

14 hat modifiers of WNK signaling may be potent antihypertensive agents.

15 A/C-selective antagonists might be desirable antihypertensive agents.

16 vailable ACE inhibitors or other widely used antihypertensive agents.

17 tension and preoperative use of two or fewer antihypertensive agents.

18 e of specific CLCNKB antagonists as diuretic antihypertensive agents.

19 ortic surgery, compared to patients on other antihypertensive agents.

20 irstline agents and low-dose therapy for all antihypertensive agents.

21 with SR-HTN and A-HTN who reported use of an antihypertensive agent, 94% were on at least one of the

22 t races and variation in the degree to which antihypertensive agents affect systemic blood pressure a

23 Treatment with an antihypertensive agent alone is often insufficient to co

24 testinal therapeutic system) as a third-line antihypertensive agent among 10,069 participants in the

25 lockers against 30,139 patients taking other antihypertensive agents and 3,987 patients receiving pla

26 studies have proposed an association between antihypertensive agents and cancer, but due to limitatio

27 ssociation between any of the currently used antihypertensive agents and cancer.

28 nd this association was independent of other antihypertensive agents and risk factors.

29 farin (presumably for deep-vein thrombosis), antihypertensive agents, and a statin.

30 events, change in kidney function, number of antihypertensive agents, and adverse events.

31 Utilization of antihypertensive agents appears to be the best global st

32 w doses of thiazide diuretics added to other antihypertensive agents are described.

33 were on at least one of the major classes of antihypertensive agents, but only 44% were on >/=2 class

34 thesized potentially carcinogenic effects of antihypertensive agents, but to date there is no convinc

35 he relative cardiovascular impact of various antihypertensive agents can be assessed.

36 xperimental studies of a new multiple action antihypertensive agent, carvedilol, are presented.

37 and evaluated the effects of two classes of antihypertensive agents commonly used in the clinical se

38 ous hypoglycemia among users of any class of antihypertensive agents compared with nonusers of antihy

39 or intake of medications such as aspirin and antihypertensive agents did not change the associations

40 The effects of administration of antihypertensive agents, diuretics, and lipid lowering a

41 omplicated hypertension, compared with other antihypertensive agents, first-line therapy with beta-bl

42 ypertensive patients, safety and efficacy of antihypertensive agents for coronary artery disease (CAD

43 erting enzyme (ACE) inhibitors are effective antihypertensive agents for patients with diabetes melli

44 changes and use of effective combinations of antihypertensive agents from different classes.

45 was a large increase in the use of multiple antihypertensive agents (from 36.8% to 47.7%, P(trend)<0

46 spective randomized clinical trials (RCT) of antihypertensive agents have focused on cardiovascular a

47 fficacy of drugs from three major classes of antihypertensive agents; however, comparative trials hav

48 Benefit has been demonstrated with multiple antihypertensive agents; however, some studies suggest a

49 ge-matched SHR and WKY were treated with the antihypertensive agent hydralazine administered in the d

50 urve." By decreasing the blood pressure, all antihypertensive agents improve aortic distensibility, b

51 ood pressure and (2) the effectiveness of an antihypertensive agent in ameliorating renal injury may

52 d nisoldipine with enalapril as a first-line antihypertensive agent in terms of the prevention and pr

53 mg dose remains the most commonly prescribed antihypertensive agent in the United States.

54 lood pressure < 140/90 mm Hg) without use of antihypertensive agents in 31 of 93 patients (33%).

55 betic status, or greater use of short-acting antihypertensive agents in blacks versus whites.

56 Despite evidence of efficacy of antihypertensive agents in treating hypertensive patient

57 eptor (alpha2-AR) agonists have been used as antihypertensive agents, in the management of drug withd

58 ith aliskiren is equivalent to commonly used antihypertensive agents including diuretics, ACE inhibit

59 on three, or controlled with at least four, antihypertensive agents (including a diuretic), is assoc

60 e >/=160 mm Hg despite taking at least three antihypertensive agents, including a diuretic).

61 and nifedipine, which are clinically used as antihypertensive agents, inhibited the photolabeling of

62 shing relative benefit or harm from specific antihypertensive agents is limited by the complex array

63 n), an FDA-approved drug formerly used as an antihypertensive agent, is capable of markedly increasin

64 ion-uncontrolled hypertension with 3 or more antihypertensive agents-is increasingly common in clinic

65 receptor blockers have emerged as effective antihypertensive agents, it is not known how efficacious

66 Treatment with the antihypertensive agents losartan (25 mg/kg per day) or h

67 lood pressure data and several pharmacologic antihypertensive agents makes early detection and treatm

68 e outlined with a particular emphasis on how antihypertensive agents may affect the brain.

69 ecular pathways by which specific classes of antihypertensive agents may promote, or protect, against

70 The antihypertensive agent mibefradil completely and reversi

71 , in an animal model of type 2 diabetes, the antihypertensive agent moxonidine induces a beneficial e

72 alone (n = 201) or in combination with other antihypertensive agents (n = 467), and none (n = 208).

73 unction score, need for vasopressors, use of antihypertensive agents, need for mechanical ventilation

74 rtension and the vasculoprotective effect of antihypertensive agents of different mechanisms of actio

75 ndirect comparisons to assess the effects of antihypertensive agents on incident diabetes.

76 k exercise than those treated with any other antihypertensive agent or combination (p < 0.05).

77 that CCBs offer a major advantage over other antihypertensive agents or that they should be recommend

78 0.001) and preoperative use of two or fewer antihypertensive agents (OR, 4.7; P = 0.005).

79 B and C: older age (P < .003), prior/current antihypertensive agents (P = .005), and lower registrati

80 ical therapy (with antiplatelet, statin, and antihypertensive agents plus lifestyle modification), me

81 Antihypertensive agents provide protection in normotensi

82 h beta-blocker-based therapy than with other antihypertensive agents regardless of race.

83 implications for the regulatory approval of antihypertensive agents, revisions of treatment guidelin

84 e purpose of this study was to determine the antihypertensive agent(s) more likely to mitigate an exa

85 tients' medications from mibefradil to other antihypertensive agents should be aware of these potenti

86 k activation induced by progesterone and the antihypertensive agent spironolactone, and the binding s

87 iabetic patients, such as insulin analogues, antihypertensive agents, statins, and hypoglycemic agent

88 Hence, an antihypertensive agent that reverses endothelial dysfunc

89 Seven new classes of antihypertensive agents that are currently under develop

90 nts in both groups also received concomitant antihypertensive agents that did not inhibit the renin-a

91 ertrophy and arterial mass better than other antihypertensive agents that lower blood pressure equall

92 analyses suggests that ARBs, while effective antihypertensive agents that protect against risk of str

93 We identified 7 candidate antihypertensive agents that significantly reduced AD-ty

94 and multidrug users) with that of any other antihypertensive agent, the adjusted RR was 1.42 (95% CI

95 When compared with other antihypertensive agents, there was similar but no increm

96 dy mass index, cigarette smoking, and use of antihypertensive agents, they found that glucose was a s

97 besartan, amlodipine, or placebo, with other antihypertensive agents to a BP goal of < or =135/85 mmH

98 ular events, quality of life, rate of single antihypertensive agent use, lipid levels, progression to

99 astolic function irrespective of the type of antihypertensive agent used.

100 oint of stage 1 hypertension, treatment with antihypertensive agents was initiated.

101 Other antihypertensive agents were added to achieve predetermi

102 bined therapy (with rosuvastatin and the two antihypertensive agents) with the 3168 participants assi